Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates
Bolt Biotherapeutics (NASDAQ: BOLT) has announced a key opinion leader (KOL) conference call and webcast scheduled for May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET. The event will feature Dr. Ecaterina Dumbrava from MD Anderson Cancer Center, who will discuss the Phase 1 dose-escalation clinical study results of BDC-3042 previously presented at the AACR Annual Meeting in April 2025.
During the call, Bolt's management team will also provide updates on BDC-3042 partnering plans, BDC-4182 clinical development, and first quarter 2025 financial results. A Q&A session will follow the presentations. The event will be accessible via webcast, with a replay available on the company's investor relations website.
Bolt Biotherapeutics (NASDAQ: BOLT) ha annunciato una conference call e webcast con key opinion leader (KOL) programmata per il 12 maggio 2025 alle 14:30 PT / 17:30 ET. L'evento vedrà la partecipazione della Dott.ssa Ecaterina Dumbrava del MD Anderson Cancer Center, che discuterà i risultati dello studio clinico di fase 1 con dose-escalation di BDC-3042 presentati in precedenza all'AACR Annual Meeting nell'aprile 2025.
Durante la chiamata, il team di gestione di Bolt fornirà anche aggiornamenti sui piani di partnership per BDC-3042, sullo sviluppo clinico di BDC-4182 e sui risultati finanziari del primo trimestre 2025. A seguire, ci sarà una sessione di domande e risposte. L'evento sarà accessibile tramite webcast, con una replica disponibile sul sito web per gli investitori della società.
Bolt Biotherapeutics (NASDAQ: BOLT) ha anunciado una conferencia telefónica y webcast con líderes de opinión clave (KOL) programada para el 12 de mayo de 2025 a las 2:30 p.m. PT / 5:30 p.m. ET. El evento contará con la participación de la Dra. Ecaterina Dumbrava del MD Anderson Cancer Center, quien discutirá los resultados del estudio clínico de fase 1 con escalada de dosis de BDC-3042 presentados previamente en la Reunión Anual de AACR en abril de 2025.
Durante la llamada, el equipo directivo de Bolt también proporcionará actualizaciones sobre los planes de asociación para BDC-3042, el desarrollo clínico de BDC-4182 y los resultados financieros del primer trimestre de 2025. Tras las presentaciones, habrá una sesión de preguntas y respuestas. El evento será accesible vía webcast, con una repetición disponible en el sitio web de relaciones con inversores de la compañía.
Bolt Biotherapeutics (NASDAQ: BOLT)는 2025년 5월 12일 오후 2시 30분 PT / 오후 5시 30분 ET에 주요 의견 리더(KOL) 컨퍼런스 콜 및 웹캐스트를 개최할 예정임을 발표했습니다. 이번 행사에는 MD Anderson Cancer Center의 Dr. Ecaterina Dumbrava가 참여하여 2025년 4월 AACR 연례 회의에서 발표된 BDC-3042 1상 용량 증량 임상 연구 결과에 대해 논의할 예정입니다.
콜 동안 Bolt의 경영진은 BDC-3042 파트너십 계획, BDC-4182 임상 개발 상황, 2025년 1분기 재무 결과에 대한 업데이트도 제공할 것입니다. 발표 후 질의응답 시간이 있을 예정입니다. 행사는 웹캐스트를 통해 참여할 수 있으며, 회사 투자자 관계 웹사이트에서 다시보기 서비스를 제공합니다.
Bolt Biotherapeutics (NASDAQ: BOLT) a annoncé une conférence téléphonique et un webcast avec des leaders d'opinion clés (KOL) prévus le 12 mai 2025 à 14h30 PT / 17h30 ET. L'événement mettra en vedette la Dr Ecaterina Dumbrava du MD Anderson Cancer Center, qui présentera les résultats de l'étude clinique de phase 1 avec escalade de dose de BDC-3042 précédemment exposés lors de la réunion annuelle de l'AACR en avril 2025.
Lors de l'appel, l'équipe de direction de Bolt fournira également des mises à jour sur les plans de partenariat pour BDC-3042, le développement clinique de BDC-4182, ainsi que les résultats financiers du premier trimestre 2025. Une session de questions-réponses suivra les présentations. L'événement sera accessible via webcast, avec une rediffusion disponible sur le site web des relations investisseurs de la société.
Bolt Biotherapeutics (NASDAQ: BOLT) hat eine Telefonkonferenz und Webcast mit Key Opinion Leadern (KOL) für den 12. Mai 2025 um 14:30 Uhr PT / 17:30 Uhr ET angekündigt. Bei der Veranstaltung wird Dr. Ecaterina Dumbrava vom MD Anderson Cancer Center die Ergebnisse der Phase-1-Dosis-Eskalationsstudie von BDC-3042 vorstellen, die zuvor auf dem AACR-Jahrestreffen im April 2025 präsentiert wurden.
Während des Calls wird das Management von Bolt außerdem Updates zu den Partnerschaftsplänen für BDC-3042, der klinischen Entwicklung von BDC-4182 und den Finanzergebnissen des ersten Quartals 2025 geben. Im Anschluss an die Präsentationen findet eine Fragerunde statt. Die Veranstaltung ist per Webcast zugänglich, eine Wiederholung steht auf der Investor-Relations-Website des Unternehmens zur Verfügung.
- None.
- None.
- Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET
REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will host a key opinion leader (KOL) conference call and webcast featuring Ecaterina Dumbrava, M.D., associate professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center and investigator on the Phase 1 dose-escalation clinical study of BDC-3042, on Monday, May 12, 2025 at 2:30 p.m. PT / 5:30 p.m. ET.
Dr. Dumbrava will discuss the results from the Phase 1 dose-escalation clinical study of BDC-3042 that were presented at the American Associates for Cancer Research (AACR) Annual Meeting that took place in April 2025. In addition, Bolt’s management team will discuss BDC-3042 partnering plans, present an update on BDC-4182 clinical development, and provide an update on first quarter 2025 financial results. A live Q&A will follow the prepared remarks.
Conference Call and Webcast Details:
Bolt Biotherapeutics will host a conference call and webcast featuring Dr. Dumbrava on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET. The conference call and webcast can be accessed via this link https://edge.media-server.com/mmc/p/q6d3u5uv/. A replay of the event will be available for a limited time under Events and Presentations in the Investors section of the Company’s website at investors.boltbio.com/events-and-presentations.
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development. The Company’s pipeline includes BDC-3042, a first-in-class agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next-generation Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is currently in a Phase 1 dose escalation trial that includes patients with any of seven different solid tumor types. BDC-4182 is supported by strong in vitro and in vivo data demonstrating potent anti-tumor activity, and activities are underway to support the initiation of clinical trials in second quarter 2025. Bolt Biotherapeutics is also developing additional Boltbody™ ISACs in strategic collaborations with leading biopharmaceutical companies. For more information, please visit https://www.boltbio.com/.
Investor Relations and Media Contact:
Matthew DeYoung
Argot Partners
(212) 600-1902
boltbio@argotpartners.com
FAQ
When is Bolt Biotherapeutics (BOLT) hosting its KOL conference call to discuss BDC-3042 Phase 1 results?
Who is the key opinion leader presenting at BOLT's conference call?
What topics will be covered in Bolt Biotherapeutics' May 2025 conference call?
How can investors access Bolt Biotherapeutics' May 12 conference call?
